StockData
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc. (BIAFW) stock

BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)

Close on Oct 30, 2026Market cap $23.58MP/E –Yield –

Earnings

bioAffinity Technologies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 13, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$1.50M
+15.4% on a year earlier
EPS, Q2 FY2026
–
-$0.17 a year earlier
Latest guidance
Lowered
Mar 31, 2025 · 2 items

Quarterly results

Revenue and earnings per share from each of bioAffinity Technologies's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 13, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 7, 2026before the open$1.50M+15.4%–Release
Q1 FY2026ended Mar 31, 2026May 8, 2026before the open$1.40M-26.3%-$0.81Release
Q4 FY2025ended Dec 31, 2025Mar 13, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 14, 2025before the open$1.50M-37.5%-$4.74Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025after the close$1.30M–-$0.17Release
Q1 FY2025ended Mar 31, 2025May 15, 2025during market hours$1.90M-20.8%-$0.16Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open$2.40M+704.1%-$0.16Release
Q2 FY2024ended Jun 30, 2024Jul 9, 2024after the close–––Release
Q1 FY2024ended Mar 31, 2024May 16, 2024after the close$2.40M+239900.0%-$0.21Release
Q4 FY2023ended Dec 31, 2023Apr 1, 2024after the close$2.20M+87900.0%–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period bioAffinity Technologies guided for has been reported

Guidance history

Every forecast bioAffinity Technologies put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 31, 2025total revenueFY2025$6.00M – $8.00MNew
Mar 31, 2025sales of CyPath lung testsFY2025$1.00M – $2.00MLowered
Nov 14, 2024revenue forecastFY2024$9.60MRaised
Jul 9, 2024CyPath ® Lung salesFY2024880New
Jul 9, 2024revenueFY2024$9.20M – $9.60MReaffirmed
May 15, 2024revenuesFY2024$9.20M – $9.60MNew
Nov 15, 2023net revenuesnext 12 months (fourth quarter 2023 to third quarter 2024)$8.40M – $9.00M–
Nov 15, 2023net revenuesFY2023$2.10M – $2.30MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases bioAffinity Technologies filed with the SEC as exhibits to Form 8-K or 6-K

  1. Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness
    News
  2. Technologies to Present New Perspectives on CyPath ® Lung’s Use for Cancer Risk Assessment at CHEST 2026
    News
  3. Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and
    News
  4. Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced
    News
  5. Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced
    News
  6. Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
    News
  7. Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
    News
  8. Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with
    News
  9. Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
    News
  10. Technologies Announces Grant of Hong Kong Patent for Company’s CyPath ® Lung Noninvasive Lung Cancer Diagnostic
    News
  11. 8-K exhibit EX-99.1
    Update
  12. Technologies Regains Compliance with Nasdaq Listing Requirements
    News
  13. Technologies to Participate in the H.C. Wainwright 28 th Annual Global Investment Conference
    News
  14. Technologies Advances CyPath ® Lung for Surveillance of Lung Cancer Survivors
    News
  15. Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
    Update